---
title: "Pre-market hot trades in US stocks: AMASS Brands up 16.20% in pre-market; BiomX down 14.81% in pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287738945.md"
description: "AMASS Brands pre-market up 16.20%; BiomX pre-market down 14.81%; Soligenix pre-market up 116.37%; Founder pre-market up 69.15%; Nanoviricides pre-market up 41.72%"
datetime: "2026-05-27T08:27:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287738945.md)
  - [en](https://longbridge.com/en/news/287738945.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287738945.md)
---

# Pre-market hot trades in US stocks: AMASS Brands up 16.20% in pre-market; BiomX down 14.81% in pre-market

**Pre-market Hot Trades in US Stocks**

AMASS Brands, up 16.20% in pre-market trading, has no significant recent news. Trading is active with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

BiomX, down 14.81% in pre-market trading, has no significant recent news. Trading is active with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

**Top Gainers in Pre-market US Stocks**

Soligenix is up 116.37% in pre-market trading. Based on recent key news:

1.  On May 26, Soligenix announced that it obtained important data regarding thermal stability, immunogenicity, and efficacy against similar viruses. This progress paves the way for the rapid development of the vaccine. The company plans to use this information to accelerate the vaccine development process. This news significantly boosted the company's stock price. Source: PR Newswire. The biopharmaceutical industry has been active recently.

Founder is up 69.15% in pre-market trading, with no significant recent news. Trading is active with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Nanoviricides is up 41.72% in pre-market trading. Based on recent news,

1.  On May 26, NanoViricides Inc. announced that its new drug made significant progress in clinical trials. This news triggered a strong market reaction, with investors confident in the company's future growth prospects, driving the stock price up 41.72%. The biopharmaceutical industry has been performing strongly recently, with investor sentiment high

### Related Stocks

- [AMSS.US](https://longbridge.com/en/quote/AMSS.US.md)
- [PHGE.US](https://longbridge.com/en/quote/PHGE.US.md)
- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)
- [FGL.US](https://longbridge.com/en/quote/FGL.US.md)
- [NNVC.US](https://longbridge.com/en/quote/NNVC.US.md)

## Related News & Research

- [BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations | PHGE Stock News](https://longbridge.com/en/news/287781623.md)
- [Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention](https://longbridge.com/en/news/287809612.md)
- [Transcat (TRNS) To Report Earnings Tomorrow: Here Is What To Expect](https://longbridge.com/en/news/287487565.md)
- [11:11 ETCellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Network](https://longbridge.com/en/news/287792346.md)
- [Why double-digit earnings growth won't stop the next bear market](https://longbridge.com/en/news/287680175.md)